Transient receptor potential cation channel subfamily V member 2 (TRPV2)
Homo sapiens — UniProt Q9Y5S1
Data last refreshed: (UniProt release unknown)
Key facts
Transient receptor potential cation channel subfamily V member 2 (TRPV2) is a protein from Homo sapiens identified by UniProt accession Q9Y5S1, 764 residues long. MolForge cross-references it against 3 known binders and 223 disease associations.
- UniProt accession: Q9Y5S1; gene symbol TRPV2.
- Organism: Homo sapiens.
- Length: 764 amino acids.
- Target class: Ion channel.
- Approved drugs acting on it (DrugCentral): Loratadine, Tranilast and Cannabidiol.
- Top disease associations (Open Targets): neurodegenerative disease, glioblastoma multiforme and breast adenocarcinoma.
- 3D structure: AlphaFold model available.
Target properties
| Protein name | Transient receptor potential cation channel subfamily V member 2 |
|---|---|
| UniProt accession | Q9Y5S1 |
| Gene | TRPV2 |
| Organism | Homo sapiens |
| Length | 764 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | Ion channel (inferred from UniProt keywords / EC) |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). Approved drug exists
| Druggability tier | MEDIUM |
|---|---|
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs acting on this target (3)
Approved drugs whose DrugCentral mechanism of action is this protein, most potent first.
Disease associations (223)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.38
- glioblastoma multiforme · score 0.18
- breast adenocarcinoma · score 0.16
- lung adenocarcinoma · score 0.12
- neoplasm · score 0.10
- esophageal squamous cell carcinoma · score 0.09
- melanoma · score 0.09
- Miyoshi myopathy · score 0.08
- viral disease · score 0.08
- triple-negative breast cancer · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|---|---|---|---|
| AF-Q9Y5S1-F1 | alphafold | PREDICTED | 78.40 | — |
Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q9Y5S1.
Amino-acid sequence (764 residues)
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
Which approved drugs target TRPV2?
DrugCentral lists 3 approved drugs whose mechanism of action is TRPV2: Loratadine, Tranilast and Cannabidiol.
Which diseases are associated with TRPV2?
The strongest Open Targets associations for TRPV2 are neurodegenerative disease, glioblastoma multiforme, breast adenocarcinoma, lung adenocarcinoma and neoplasm.
How long is the TRPV2 protein?
The Homo sapiens TRPV2 protein (UniProt Q9Y5S1) is 764 amino acids long.
Browse: Targets: T · all protein targets A–Z · drugs A–Z.
Sources
- UniProtKB Q9Y5S1 — name, gene, function, sequence, keywords (CC BY 4.0)
- AlphaFold DB Q9Y5S1 — predicted 3D structure (CC BY 4.0)
- DrugCentral — approved drugs and mechanism-of-action links (CC BY-SA 4.0)
- Open Targets Platform — disease associations and tractability (CC0)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.